The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | How may serial sampling of cfDNA track disease dynamics and detect early progression in myeloma?
Marina Martello, PhD, The University of Bologna, Bologna, Italy, discusses how low-pass whole-genome sequencing (WGS) can detect a tumor fraction of cell-free DNA (cfDNA) in multiple myeloma, highlighting that serial sampling may track disease dynamics and help guide treatment decisions. Dr Martello emphasizes that blood-based testing is not yet a replacement for bone marrow assessment, but is a promising, less invasive approach to myeloma management. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
